S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.57
+1.89
+11.33%
KRYS · Krystal Biotech, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Krystal Biotech Inc (KRYS)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$321.87
-3.55
(-1.09%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$321.87
$320.06
$326.27
52-WEEK RANGE
$321.87
$183.03
$382.54
What's happening
- KRYS is down 1.09% today, trading at $321.87. — Live quote
- Volume today (42,243) is well below its 3-month average of 371,130. (Finnhub fundamentals)
- Reports earnings on 2026-11-09 (before market open), 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $1.79 actual vs. $1.69 estimated (+6.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 11
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (20 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
KRYS
+30.68%
vs S&P 500
+17.31%
1-YEAR RETURN
KRYS
+68.87%
vs S&P 500
+53.71%
6-MONTH RETURN
KRYS
+17.49%
3-MONTH RETURN
KRYS
-4.34%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$1.79
Est. $1.69
BEAT +6.0%
2026-04-26 (Q1 2026)
$1.83
Est. $1.45
BEAT +26.3%
2026-01-26 (Q4 2025)
$1.70
Est. $1.44
BEAT +18.3%
2025-10-26 (Q3 2025)
$2.66
Est. $1.11
BEAT +140.2%
Valuation Measures & Ratios
Enterprise Value4$9.09B
Forward P/E540.76
PEG Ratio61.01
Price / Sales (TTM1)21.61
Price / Book78.06
EV4 / Revenue20.64
EV4 / EBITDA44.65
Profit Margin54.82%
Operating Margin44.89%
Return on Equity (ROE8)19.34%
Return on Assets (ROA9)17.65%
Avg Volume (3M)371,130
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $11.36B | $7.88B | $5.27B | $4.09B | $5.38B |
| P/E | 49.74 | 37.64 | 29.18 | 34.98 | 67.76 |
| Price/Sales | 26.46 | 19.78 | 14.40 | 12.08 | 18.71 |
| Price/Book | 8.36 | 6.17 | 4.63 | 3.93 | 5.46 |
| EV/Revenue | 25.46 | 18.52 | 13.33 | 11.03 | 17.64 |
| ROE | 16.80% | 16.40% | 15.87% | 11.23% | 8.06% |
| ROA | 15.22% | 14.99% | 14.56% | 10.26% | 7.39% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short3,475,527
Change from Prior Settlement+9.86%
% of Float—
Days to Cover (Short Ratio)11.19
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 24.1% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 54.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is +68.9%. Finnhub market metrics ↗
Potential concerns
- Trailing P/E is 39.4, a high price relative to reported earnings. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-15; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on KRYS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $119.2M | $116.4M | $97.8M | $96.0M | $88.2M | $83.8M | $70.3M | $45.2M |
| Operating income | $58.4M | $53.7M | $41.4M | $39.4M | $36.3M | $22.5M | $8.6M | -$6.7M |
| Net income | $54.8M | $55.9M | $79.4M | $38.3M | $35.7M | $27.2M | $15.6M | $932.0K |
| EPS (diluted) | $1.79 | $1.83 | $2.66 | $1.29 | $1.20 | $0.91 | $0.53 | $0.03 |
| EPS (basic) | $1.85 | $1.91 | $2.74 | $1.33 | $1.24 | $0.95 | $0.54 | $0.03 |
| Operating margin | $49 | $46 | $42 | $41 | $41 | $27 | $12 | -$15 |
| Net margin | $46 | $48 | $81 | $40 | $41 | $32 | $22 | $2 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.50B | $1.40B | $1.33B | $1.24B | $1.14B | $1.07B | $1.06B | $982.3M |
| Total liabilities | $141.5M | $120.2M | $114.2M | $102.2M | $97.7M | $89.7M | $109.5M | $96.5M |
| Stockholders' equity | $1.36B | $1.28B | $1.22B | $1.14B | $1.04B | $984.7M | $946.4M | $885.8M |
| Total current assets | $1.06B | $1.02B | $1.02B | $925.6M | $841.3M | $766.8M | $742.0M | $713.2M |
| Total current liabilities | $127.4M | $107.8M | $102.9M | $91.3M | $86.9M | $79.5M | $102.0M | $89.5M |
| Cash & equivalents | $427.7M | $501.3M | $496.3M | $392.6M | $353.8M | $308.8M | $344.9M | $374.0M |
| Accounts receivable | $138.7M | $127.0M | $127.4M | $129.6M | $111.4M | $103.3M | $104.7M | $97.3M |
| Inventory | $45.6M | $42.6M | $40.5M | $37.6M | $31.0M | $29.9M | $26.5M | $18.6M |
| Other current assets | — | — | — | — | — | — | — | — |
| Marketable securities (non-current) | $257.3M | $193.5M | $128.1M | $133.1M | $138.8M | $148.5M | $152.1M | $105.9M |
| Property, plant & equipment | $153.8M | $153.6M | $150.8M | $148.9M | $150.4M | $151.1M | $155.2M | $156.6M |
| Other non-current assets | $284.0K | $300.0K | $287.0K | $333.0K | $197.0K | $218.0K | $231.0K | $203.0K |
| Accounts payable | $6.5M | $4.1M | $3.2M | $2.1M | $7.1M | $2.7M | $5.0M | $5.6M |
| Other current liabilities | $3.4M | $3.2M | $3.6M | $3.3M | $2.2M | $3.4M | $2.4M | $2.6M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $7.1M | $5.1M | $3.7M | $3.1M | $2.8M | $2.0M | $1.4M | $761.0K |
| Common stock & paid-in capital | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Retained earnings | $134.9M | $80.1M | $24.2M | -$27.2M | -$106.6M | -$144.9M | -$180.7M | -$226.1M |
| Accumulated other comprehensive income (loss) | -$4.3M | -$1.6M | $1.1M | $1.1M | $1.2M | $390.0K | -$190.0K | $1.5M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $74.8M | $80.4M | $77.5M | $39.7M | $52.7M | $31.0M | $52.8M | $58.9M |
| Investing cash flow | -$161.6M | -$63.6M | $11.2M | -$4.3M | -$10.5M | -$54.8M | -$83.8M | -$34.3M |
| Financing cash flow | $15.1M | -$10.5M | $15.7M | $3.7M | $1.8M | -$12.5M | $2.4M | $3.4M |
| Free cash flow | $71.2M | $73.2M | $75.4M | $38.0M | $50.8M | $24.8M | $52.0M | $57.8M |
| Capital expenditures | $3.6M | $7.1M | $2.1M | $1.7M | $1.9M | $6.2M | $801.0K | $1.0M |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $14.2M | $13.6M | $13.8M | $13.2M | $14.1M | $13.5M | $13.4M | $13.3M |
| Deferred income taxes | — | — | -$27.3M | — | — | — | $0 | — |
| Change in accounts receivable | $12.0M | -$58.0K | -$2.5M | $17.9M | $8.2M | -$1.5M | $7.4M | -$5.9M |
| Change in inventory | $958.0K | $243.0K | $1.1M | $4.7M | -$880.0K | $1.4M | $6.5M | $3.7M |
| Change in accounts payable | $3.1M | $1.0M | -$183.0K | -$4.0M | $4.1M | $906.0K | -$591.0K | $91.0K |
| Purchases of investments | $258.0M | $160.0M | — | — | $113.9M | $137.8M | — | — |
| Sales/maturities of investments | — | — | — | $289.9M | — | — | — | $238.0M |
| Tax withholding on stock comp | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $389.1M | $290.5M | $50.7M | $0 | $0 |
| Operating income | $161.3M | $65.7M | -$109.6M | -$145.2M | -$68.3M |
| Net income | $204.8M | $89.2M | $10.9M | -$140.0M | -$69.6M |
| EPS (diluted) | $6.84 | $3.00 | $0.39 | $-5.49 | $-3.13 |
| EPS (basic) | $7.08 | $3.12 | $0.40 | $-5.49 | $-3.13 |
| Operating margin | $41 | $23 | -$216 | — | — |
| Net margin | $53 | $31 | $22 | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $1.33B | $1.06B | $818.4M | $558.5M | $626.3M |
| Total liabilities | $114.2M | $109.5M | $39.7M | $36.2M | $32.7M |
| Stockholders' equity | $1.22B | $946.4M | $778.6M | $522.2M | $593.6M |
| Total current assets | $1.02B | $742.0M | $587.9M | $383.8M | $442.3M |
| Total current liabilities | $102.9M | $102.0M | $33.1M | $28.8M | $25.7M |
| Cash & equivalents | $496.3M | $344.9M | $358.3M | $161.9M | $341.2M |
| Accounts receivable | $127.4M | $104.7M | $42.0M | $0 | — |
| Inventory | $40.5M | $26.5M | $7.0M | $0 | — |
| Other current assets | — | — | — | — | — |
| Marketable securities (non-current) | $128.1M | $152.1M | $62.0M | $4.6M | $64.4M |
| Property, plant & equipment | $150.8M | $155.2M | $161.2M | $161.7M | $112.4M |
| Other non-current assets | $287.0K | $231.0K | $263.0K | $324.0K | $74.0K |
| Accounts payable | $3.2M | $5.0M | $4.1M | $4.0M | $8.4M |
| Other current liabilities | $3.6M | $2.4M | $2.2M | $267.0K | $87.0K |
| Long-term debt | — | — | — | — | — |
| Other non-current liabilities | $3.7M | $1.4M | $0 | — | — |
| Common stock & paid-in capital | $0 | $0 | $0 | $0 | $0 |
| Retained earnings | $24.2M | -$180.7M | -$269.8M | -$280.8M | -$140.8M |
| Accumulated other comprehensive income (loss) | $1.1M | -$190.0K | $638.0K | -$728.0K | -$163.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $200.9M | $123.4M | -$88.8M | -$100.6M | -$47.9M |
| Investing cash flow | -$58.4M | -$163.4M | $82.6M | -$114.1M | -$226.8M |
| Financing cash flow | $8.7M | $27.0M | $202.8M | $35.3M | $347.7M |
| Free cash flow | $188.9M | $119.2M | -$100.6M | -$153.5M | -$116.3M |
| Capital expenditures | $12.0M | $4.2M | $11.8M | $53.0M | $68.3M |
| Depreciation & amortization | — | — | — | $4.1M | $2.8M |
| Share-based compensation | $54.5M | $49.1M | $39.9M | $33.2M | $15.3M |
| Deferred income taxes | -$27.3M | $0 | $0 | $0 | $0 |
| Change in accounts receivable | $22.1M | $62.7M | $42.0M | $0 | $0 |
| Change in inventory | $6.3M | $11.9M | $4.5M | $0 | $0 |
| Change in accounts payable | $826.0K | $1.0M | -$101.0K | -$1.3M | $712.0K |
| Tax withholding on stock comp | — | — | $749.0K | $649.0K | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding KRYS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-07-14 to 2026-09-04
Recent transactions
- Insiders have net sold 126,642 shares over the last 182 days, across 0 purchases and 58 sales.
- Most recent: Krishnan Suma (President, R&D) — Open market sale of 520 shares on 2026-09-04.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)126,642 sh(58 txns)
Net Shares-126,642
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Krishnan Suma | President, R&D | Open market sale | 2026-09-04 | 520 |
| Krishnan Krish S | President and CEO | Open market sale | 2026-09-04 | 520 |
| ROSSI DINO A | Director | Gift | 2026-08-14 | 3,691 |
| Thomas John Charles | EVP, General Counsel | Option exercise | 2026-06-25 | 1,000 |
| ROMANO KATHRYN | Chief Accounting Officer | Open market sale | 2026-03-02 | 750 |
| JANNEY DANIEL | Director | Open market sale | 2026-02-27 | 9,430 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-04 | Krishnan Suma | President, R&D | Open market sale | 520 | $354.54 |
| 2026-09-04 | Krishnan Suma | President, R&D | Open market sale | 2,006 | $355.57 |
| 2026-09-04 | Krishnan Suma | President, R&D | Open market sale | 3,267 | $356.37 |
| 2026-09-04 | Krishnan Suma | President, R&D | Open market sale | 3,962 | $357.57 |
| 2026-09-04 | Krishnan Suma | President, R&D | Open market sale | 3,180 | $358.42 |
| 2026-09-04 | Krishnan Suma | President, R&D | Open market sale | 3,392 | $359.39 |
| 2026-09-04 | Krishnan Suma | President, R&D | Open market sale | 2,320 | $360.47 |
| 2026-09-04 | Krishnan Suma | President, R&D | Open market sale | 1,242 | $361.61 |
| 2026-09-04 | Krishnan Suma | President, R&D | Open market sale | 1,992 | $362.65 |
| 2026-09-04 | Krishnan Suma | President, R&D | Open market sale | 565 | $363.34 |
| 2026-09-04 | Krishnan Suma | President, R&D | Open market sale | 1,329 | $364.48 |
| 2026-09-04 | Krishnan Suma | President, R&D | Open market sale | 826 | $365.41 |
| 2026-09-04 | Krishnan Suma | President, R&D | Open market sale | 399 | $366.56 |
| 2026-09-04 | Krishnan Krish S | President and CEO | Open market sale | 520 | $354.54 |
| 2026-09-04 | Krishnan Krish S | President and CEO | Open market sale | 2,029 | $355.57 |
| 2026-09-04 | Krishnan Krish S | President and CEO | Open market sale | 3,297 | $356.37 |
| 2026-09-04 | Krishnan Krish S | President and CEO | Open market sale | 3,981 | $357.57 |
| 2026-09-04 | Krishnan Krish S | President and CEO | Open market sale | 3,143 | $358.42 |
| 2026-09-04 | Krishnan Krish S | President and CEO | Open market sale | 3,357 | $359.39 |
| 2026-09-04 | Krishnan Krish S | President and CEO | Open market sale | 2,266 | $360.46 |
| 2026-09-04 | Krishnan Krish S | President and CEO | Open market sale | 1,214 | $361.61 |
| 2026-09-04 | Krishnan Krish S | President and CEO | Open market sale | 2,010 | $362.65 |
| 2026-09-04 | Krishnan Krish S | President and CEO | Open market sale | 573 | $363.34 |
| 2026-09-04 | Krishnan Krish S | President and CEO | Open market sale | 1,358 | $364.48 |
| 2026-09-04 | Krishnan Krish S | President and CEO | Open market sale | 847 | $365.42 |
| 2026-09-04 | Krishnan Krish S | President and CEO | Open market sale | 405 | $366.56 |
| 2026-08-14 | ROSSI DINO A | Director | Gift | 3,691 | $0.00 |
| 2026-08-14 | ROSSI DINO A | Director | Open market sale | 341 | $325.60 |
| 2026-08-14 | ROSSI DINO A | Director | Open market sale | 2,287 | $326.60 |
| 2026-08-14 | ROSSI DINO A | Director | Open market sale | 5,226 | $327.39 |
| 2026-08-14 | ROSSI DINO A | Director | Open market sale | 1,687 | $328.52 |
| 2026-08-14 | ROSSI DINO A | Director | Open market sale | 7,428 | $329.60 |
| 2026-08-14 | ROSSI DINO A | Director | Open market sale | 4,896 | $330.36 |
| 2026-08-14 | ROSSI DINO A | Director | Open market sale | 3,095 | $331.43 |
| 2026-08-14 | ROSSI DINO A | Director | Open market sale | 40 | $333.23 |
| 2026-06-25 | Thomas John Charles | EVP, General Counsel | Option exercise | 1,000 | $179.25 |
| 2026-06-25 | Thomas John Charles | EVP, General Counsel | Open market sale | 1,000 | $347.27 |
| 2026-06-04 | Krishnan Suma | President, R&D | Open market sale | 320 | $300.75 |
| 2026-06-04 | Krishnan Suma | President, R&D | Open market sale | 593 | $302.25 |
| 2026-06-04 | Krishnan Suma | President, R&D | Open market sale | 247 | $303.17 |
| 2026-06-04 | Krishnan Suma | President, R&D | Open market sale | 400 | $304.89 |
| 2026-06-04 | Krishnan Suma | President, R&D | Open market sale | 480 | $305.87 |
| 2026-06-04 | Krishnan Suma | President, R&D | Open market sale | 1,348 | $307.09 |
| 2026-06-04 | Krishnan Suma | President, R&D | Open market sale | 12,729 | $307.81 |
| 2026-06-04 | Krishnan Suma | President, R&D | Open market sale | 3,803 | $308.89 |
| 2026-06-04 | Krishnan Suma | President, R&D | Open market sale | 2,801 | $309.95 |
| 2026-06-04 | Krishnan Suma | President, R&D | Open market sale | 2,039 | $310.94 |
| 2026-06-04 | Krishnan Suma | President, R&D | Open market sale | 240 | $311.65 |
| 2026-06-04 | Krishnan Krish S | President and CEO | Open market sale | 320 | $300.75 |
| 2026-06-04 | Krishnan Krish S | President and CEO | Open market sale | 640 | $302.24 |
| 2026-06-04 | Krishnan Krish S | President and CEO | Open market sale | 176 | $303.17 |
| 2026-06-04 | Krishnan Krish S | President and CEO | Open market sale | 544 | $304.81 |
| 2026-06-04 | Krishnan Krish S | President and CEO | Open market sale | 589 | $306.33 |
| 2026-06-04 | Krishnan Krish S | President and CEO | Open market sale | 11,461 | $307.68 |
| 2026-06-04 | Krishnan Krish S | President and CEO | Open market sale | 4,830 | $308.47 |
| 2026-06-04 | Krishnan Krish S | President and CEO | Open market sale | 2,784 | $309.49 |
| 2026-06-04 | Krishnan Krish S | President and CEO | Open market sale | 2,652 | $310.43 |
| 2026-06-04 | Krishnan Krish S | President and CEO | Open market sale | 964 | $311.36 |
| 2026-06-04 | Krishnan Krish S | President and CEO | Open market sale | 40 | $312.23 |
| 2026-05-26 | Thomas John Charles | EVP, General Counsel | Open market sale | 642 | $302.03 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:50 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-15 | 8-K | 2026-10-15 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-04 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-04 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-14 | View on SEC.gov → |
| 2026-08-03 | 8-K | 2026-08-03 | View on SEC.gov → |
| 2026-08-03 | 10-Q | 2026-06-30 | View on SEC.gov → |
Recent news
Headlines about KRYS (Krystal Biotech, Inc.). Links open the publisher — we don’t host full articles.
-
Krystal Biotech, Inc. (KRYS) Stock Forecasts
Yahoo Finance · 2026-10-22 -
KRYS261016C00350000 Interactive Stock Chart | KRYS Oct 2026 350.000 call Stock
Yahoo Finance · 2026-10-21 -
Cystic Fibrosis Market Poised for Growth During the Forecast Period (2026-2036) as CFTR Modulators Transform Treatment Landscape | DelveInsight
Yahoo · 2026-10-21 -
Regeneron, Vidac Pharma, Krystal Biotech: New Active Ingredients, Enormous Stock Market Potential
Stockhouse · 2026-10-21 -
KRYS Mar 2027 260.000 put (KRYS270319P00260000) interactive stock chart
Yahoo Finance UK · 2026-10-20 -
HC Wainwright keeps USD 361 target for Krystal Biotech stock
AD HOC NEWS · 2026-10-20 -
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism
Stocktwits · 2026-10-17 -
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome
Yahoo · 2026-10-16
No headlines in this category right now — try “All”.